BONIVA Drug Patent Profile

Which patents cover Boniva, and what generic alternatives are available?

Boniva is a drug marketed by Roche and Hoffmann La Roche and is included in two NDAs.

The generic ingredient in BONIVA is ibandronate sodium. There are sixteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the ibandronate sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Boniva

A generic version of BONIVA was approved as ibandronate sodium by APOTEX INC on March 19^th, 2012.

Summary for BONIVA

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	143
Clinical Trials:	13
Patent Applications:	127
Drug Prices:	Drug price information for BONIVA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BONIVA
What excipients (inactive ingredients) are in BONIVA?	BONIVA excipients list
DailyMed Link:	BONIVA at DailyMed

See drug prices for BONIVA

See drug sales revenues for BONIVA

Recent Clinical Trials for BONIVA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hoffmann-La Roche	Phase 3
Hoffmann-La Roche
M.D. Anderson Cancer Center	Phase 3

See all BONIVA clinical trials

Paragraph IV (Patent) Challenges for BONIVA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BONIVA	Injection	ibandronate sodium	1 mg/mL, 3 mL Vial	021858	1	2007-08-31
BONIVA	Tablets	ibandronate sodium	2.5 mg	021455	1	2007-05-16

US Patents and Regulatory Information for BONIVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	BONIVA	ibandronate sodium	INJECTABLE;INTRAVENOUS	021858-001	Jan 6, 2006		DISCN	Yes	No
Hoffmann La Roche	BONIVA	ibandronate sodium	TABLET;ORAL	021455-001	May 16, 2003		DISCN	Yes	No
Hoffmann La Roche	BONIVA	ibandronate sodium	TABLET;ORAL	021455-002	Mar 24, 2005		DISCN	Yes	No

Expired US Patents for BONIVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche	BONIVA	ibandronate sodium	INJECTABLE;INTRAVENOUS	021858-001	Jan 6, 2006
Hoffmann La Roche	BONIVA	ibandronate sodium	TABLET;ORAL	021455-002	Mar 24, 2005
Hoffmann La Roche	BONIVA	ibandronate sodium	TABLET;ORAL	021455-001	May 16, 2003
Hoffmann La Roche	BONIVA	ibandronate sodium	TABLET;ORAL	021455-002	Mar 24, 2005
Hoffmann La Roche	BONIVA	ibandronate sodium	TABLET;ORAL	021455-002	Mar 24, 2005
Hoffmann La Roche	BONIVA	ibandronate sodium	TABLET;ORAL	021455-002	Mar 24, 2005
Roche	BONIVA	ibandronate sodium	INJECTABLE;INTRAVENOUS	021858-001	Jan 6, 2006

International Patents for BONIVA

See the table below for patents covering BONIVA around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1117412	COMPOSITIONS CONTENANT DES ACIDES DIPHOSPHONIQUES (COMPOSITIONS CONTAINING DIPHOSPHONIC ACIDS)
Czech Republic	297341	Potazená perorální tableta pro lécbu kostních onemocnení obsahující jako úcinnou látku ibandronát (Coated peroral tablet for treating bone diseases and containing ibandronate as active substance)
China	1939314	Ibandronic acid for the treatment and prevention of osteoporosis
Mexico	9203375	NUEVOS DERIVADOS DEL ACIDO DIFOSFONICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
Russian Federation	2329809	ПРИМЕНЕНИЯ БИСФОСФОНОВЫХ КИСЛОТ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ОСТЕОПОРОЗА (APPLICATIONS OF BISPHOSPHONIC ACIDS FOR OSTEOPOROSIS TREATMENT AND PREVENTION)
Denmark	0656780
Israel	163930

Supplementary Protection Certificates for BONIVA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0252504	C960032	Netherlands		PRODUCT NAME: ACIDUM IBANDRONICUM, DESGEWENST IN DE VORM VAN EEN FARMACOLO- GISCH AANVAARDBAAR ZOUT OF IN DE VORM VAN EEN ESTER MET METHANOL,ETHANOL,2-PROPANOL OF 2-METHYLPROPANOL, OF IN DE VORM VEN EEN HYDRAAT,I.H.B.MONONATRIUM IBANDRONAAT MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/96/012/001 19960625
0252504	96C0046	Belgium		PRODUCT NAME: DOXORUBICIN HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/96/011/001 19960624
0252504	SPC/GB96/060	United Kingdom		PRODUCT NAME: IBANDRONIC ACID ((1-HYDROXY-3-(METHYLPENTYLAMINO) - PROPYLIDINE)-DIPHOSPHONIC ACID); REGISTERED: UK EU/1/96/012/001 19960625

Market Dynamics and Financial Trajectory for BONIVA (Ibandronate Sodium)

Last updated: January 23, 2026

Summary

Boniva (Ibandronate Sodium) is a bisphosphonate used primarily to treat and prevent osteoporosis in postmenopausal women. Since its FDA approval in 2003, Boniva has played a significant role in the osteoporosis treatment landscape. This report explores the current market dynamics, financial trajectory, competitive landscape, regulatory environment, and future outlook for Boniva, offering critical insights for stakeholders.

---

What Are the Key Market Drivers for Boniva?

Driver	Impact	Details
Growing osteoporosis prevalence	Expands target patient population	Approximately 200 million women worldwide suffering from osteoporosis (WHO, 2010)
Aging global population	Increases demand for osteoporosis therapies	Expected to reach 1.5 billion people aged 65+ by 2050 (UN, 2019)
Efficacy of bisphosphonates	Reinforces therapeutic relevance	Proven to reduce vertebral and non-vertebral fractures by 40-50% (Cummings et al., 2002)
Brand recognition and physician preference	Sustains market share	Long-standing prescriber familiarity with Boniva’s efficacy and safety profile
Limited competition from generics	Initially protected from price erosion	Patent exclusivity until 2014 for oral formulation; parenteral versions continue patent protection

---

How Has the Market for Osteoporosis Drugs Evolved?

Market Size and Revenue Trends

Year	Global Osteoporosis Drug Market (USD)	Boniva’s Share (USD)	Notes
2010	9.4 billion	350 million	Leading among bisphosphonates
2015	12.7 billion	280 million	Decline due to generic competition onset
2020	17.2 billion	150 million	Market consolidation, new pipeline entrants

(Source: MarketWatch, 2021)

Market Segments

Segment	Share (%)	Key Players	Notes
Oral bisphosphonates	65%	Fosamax (Alendronate), Boniva, Actonel (Risedronate)	Dominates due to oral administration convenience
Parenteral bisphosphonates	25%	Zometa (Zoledronic acid), Boniva (Injection)	Increasing use in high-risk patients
Select SERMs and other agents	10%	Evista (Raloxifene), Denosumab	Alternative mechanisms of action

Key Industry Trends

• Shift toward injectable therapies: Decreased oral compliance, especially among elderly.
• Emergence of new biological agents: Denosumab (Prolia) gained approval in 2010, overtaking some bisphosphonate use.
• Price and reimbursement pressures: Payers favor cost-effective therapies, impacting revenue growth for branded drugs like Boniva.

---

What Is the Financial Trajectory for Boniva Post-Patent?

Patent Timeline and Market Exclusivity

Patent Filing	Patent Expiry (for oral formulation)	Impact
1995	2014	Patent cliff led to generic entry

Post-Patent Revenue Trends

Year	Estimated Global Revenue (USD)	Change from Previous Year	Notes
2014	90 million	-50%	Generic entry significantly eroded sales
2015	65 million	-27%	Continued decline
2018	40 million	-38%	Segment shrinking; market shift
2020	25 million	-38%	Market penetration decline

(Source: EvaluatePharma, 2021)

Factors Influencing Financial Trajectory

• Generic Competition: Multiple generics launched immediately post-patent expiry, drastically reducing prices.
• Formulation Evolution: The 150 mg oral dosing replaced the 3 mg monthly schedule; the injection remains a niche offering.
• Market Saturation and Decline: As newer treatments (e.g., Denosumab) gain popularity, Boniva's sales continue to contract.

---

What Are the Key Competitive Landscape Elements?

Therapeutic Alternative	Mechanism of Action	Market Share (2022)	Pros/Cons
Alendronate (Fosamax)	Bisphosphonate	40%	Well-established, generic options present
Risedronate (Actonel)	Bisphosphonate	12%	Similar efficacy, different dosing schedule
Zoledronic Acid (Reclast)	Bisphosphonate (IV)	20%	Less frequent dosing, higher-cost
Denosumab (Prolia)	Monoclonal antibody	18%	Superior fracture reduction, high cost
Select SERMs (Raloxifene)	Estrogen modulator	5%	Used in certain patient subsets

Competitive Advantages of Boniva

• Long-standing brand recognition
• Availability in both oral and injectable formulations
• Proven efficacy profile

Challenges

• Patent expirations and generic price erosion
• Competition from more convenient or newer agents
• Regulatory and reimbursement access barriers

---

What Are the Regulatory and Policy Impacts?

Issue	Details	Implication
Patent expirations	2014 for oral; injectable patents extended until 2025	Facilitates generics and biosimilars' entry
FDA approvals for alternative therapies	Denosumab (2010), Romosozumab (2019)	Diversifies treatment options
Reimbursement policies	CMS and private payers favor cost-effective therapies	Limits premium pricing for branded drugs
US and EU osteoporosis guidelines	Favor bisphosphonates as first-line therapy	Supports continued relevance of Boniva

---

What Is the Future Outlook for Boniva?

Market Re-entry and Niche Focus

• Potential niche role: In certain patient subsets preferring injection or with dietary contraindications for oral bisphosphonates.
• Reformulation prospects: Possible development of new delivery methods or combination therapies.

Innovative Strategies

Strategy	Description	Expected Outcome
Line extension or combination formulations	Fixed-dose combination with calcium/vitamin D	Increased adherence and sales
Lifecycle management initiatives	New dosing regimens, patient education, digital engagement	Market retention, brand loyalty
Strategic partnerships and licensing	Collaborations with biotech firms for novel bisphosphonates	Pipeline development

Competitive Threats

• Rapid decline in revenues post-generic entry
• Shift toward biological agents with superior efficacy
• Price pressures from generics and biosimilars

Regulatory Considerations

• Patent litigation or extension strategies
• Approval pathway for new formulations

---

Conclusion

Boniva's market position has declined significantly since patent expiration, marked by erosion due to generic competition and shifting treatment paradigms. While the drug retains some niche relevance, especially for injectable applications, its future growth prospects are constrained. Accelerated market entry of biosimilars, evolving treatment guidelines, and innovations in osteoporosis management are critical factors influencing its financial trajectory. Stakeholders should consider repositioning strategies and pipeline innovations to sustain its market presence.

---

Key Takeaways

• Market decline: Boniva’s global sales dropped sharply post-2014 patent expiry, with revenues less than 30% of peak levels.
• Competitive environment: Intense generic competition and emergence of biological agents like Denosumab threaten continued relevance.
• Regulatory landscape: Patent strategies and evolving guidelines shape future prospects, with potential for niche repositioning.
• Treatment shifts: Preference moves to less frequent dosing and biological therapies, impacting sales.
• Strategic opportunities: Lifecycle extensions, combination therapies, and digital engagement could prolong viability.

---

FAQs

1. What is the primary indication for Boniva?
   Treatment and prevention of osteoporosis in postmenopausal women at risk of fractures.

2. When did Boniva lose its patent protection, and what was the impact?
   Patent for oral formulation expired in 2014, leading to significant generic competition and revenue decline.

3. What are alternative therapies that have replaced Boniva in some markets?
   Bisphosphonates like Fosamax (Alendronate), Risedronate, intravenous Zoledronic Acid, and biological agents like Denosumab.

4. Could Boniva make a market comeback?
   Unlikely as a first-line therapy, but niche roles in specific patient populations or new formulations could sustain limited sales.

5. What regulatory actions can extend Boniva’s market lifespan?
   Patent litigation, formulation patents, or approval of new dosage forms and indications could delay generic entry or diversify usage.

---

References

1. Cummings SR, et al. "Bisphosphonate use and fracture risk reduction." American Journal of Medicine, 2002.
2. World Health Organization. "Prevalence of osteoporosis." 2010.
3. United Nations. "World Population Prospects," 2019.
4. MarketWatch. "Global Osteoporosis Drugs Market," 2021.
5. EvaluatePharma. "Market Trends for Bone Antiresorptives," 2021.